SCHEMBL4385552

SCHEMBL4385552

CC(=O)c1sc(-c2ccnc(Nc3ccc(Cl)nc3)n2)nc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 7/20 0.50
ZAP70 P43403 6/20 0.50
ALDH1A1 P00352 2/20 0.48
CDK2 P24941 7/20 0.45
SRC P12931 4/20 0.45
RAB9A P51151 1/20 0.44
CDK4 P11802 4/20 0.44
PLK1 P53350 3/20 0.44
CCNA2 P20248 1/20 0.44
AURKA O14965 1/20 0.42
CDK1 P06493 1/20 0.42
CDK7 P50613 1/20 0.42
CDK9 P50750 1/20 0.42
AURKB Q96GD4 1/20 0.42
DHODH Q02127 1/20 0.42
KMT2A Q03164 1/20 0.41
PIK3CG P48736 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4389627 0.88 CDK2 (0.58) SYKZAP70ALDH1A1CDK2SRC
SCHEMBL4397546 0.84 CDK2 (0.50) SYKZAP70CDK2SRCCDK4
SCHEMBL4395177 0.83 ALDH1A1 (0.51) SYKZAP70ALDH1A1CDK2SRC
SCHEMBL4391924 0.82 SYK (0.43) SYKZAP70CDK2SRCCDK4
SCHEMBL4393948 0.80 CDC7 (0.59) SYKZAP70CDK2SRCKMT2A
SCHEMBL4384008 0.80 SYK (0.48) SYKZAP70CDK2SRCCDK4
SCHEMBL5220809 0.79 SYK (0.50) SYKZAP70CDK2SRCCDK4
SCHEMBL4385796 0.79 CDK2 (0.58) SYKZAP70CDK2SRCRAB9A
SCHEMBL5620875 0.75 CDK2 (0.76) CDK2CDK4PLK1AURKACDK1
SCHEMBL4387241 0.75 LMNA (0.55) SYKZAP70ALDH1A1CDK2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 SYK 3919/4885ZAP70 3319/4885ALDH1A1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.